Efficacy and Safety of Inebilizumab in IgG4-Related Disease ... - PubMed
Inebilizumab, targeting CD19+ B cells, is tested in the first international, double-blind, placebo-controlled trial (MITIGATE) for preventing flares in IgG4-RD, a disease causing organ dysfunction and reduced quality of life. The trial aims to assess efficacy, safety, and impact on glucocorticoid use, with 160 participants across 22 countries.
Related Clinical Trials
Reference News
Efficacy and Safety of Inebilizumab in IgG4-Related Disease ... - PubMed
Inebilizumab, targeting CD19+ B cells, is tested in the first international, double-blind, placebo-controlled trial (MITIGATE) for preventing flares in IgG4-RD, a disease causing organ dysfunction and reduced quality of life. The trial aims to assess efficacy, safety, and impact on glucocorticoid use, with 160 participants across 22 countries.